Given Cargos progress to date and its experienced leadership team Cargo is wellpositioned to be firsttomarket with an autologous CD22 CAR Tcell therapy Reid Huber a partner at Third Rock Ventures said at the time. That projection hinges on the biotechs ability to fund its clinical trial plans